Saturday, December 6, 2025

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Eco-Aggression? North Korea’s Latest Tactic Includes Hundreds of Garbage Balloons

It has been confirmed that North Korea launched over 300 trash balloons toward South Korea on the night of June 9.

The Next Trillion-Dollar Bet: Korean Pharma Invests in Immuno-Oncology, Targeting a $1 Trillion Global Market

Cho Yong-joon outlines Dongkoo Bio's transformation into a global healthcare leader, emphasizing convergence and innovative growth strategies.

Tag: AMCHAM

North KoreaKoreaKimSouth KoreaMilitaryAImarketchinaRussia

No posts to display

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.